Bucci, Marco http://orcid.org/0000-0002-5206-8651
Bluma, Marina
Savitcheva, Irina
Ashton, Nicholas J.
Chiotis, Konstantinos http://orcid.org/0000-0002-5679-0297
Matton, Anna
Kivipelto, Miia
Di Molfetta, Guglielmo
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Nordberg, Agneta http://orcid.org/0000-0001-7345-5151
Funding for this research was provided by:
Vetenskapsrådet (05817, 02965, 06086, 2017-06086, 2017-06086, 2017-00915, 2022-00732, 2022-01018)
Stiftelsen för Strategisk Forskning
Michael J. Fox Foundation for Parkinson’s Research (MJJF-019728)
Hjärnfonden (FO2017-0243, ALZ2022-0006, FO2022-0270)
EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236, JPND2021-00694)
EC | Horizon 2020 Framework Programme (101053962)
Alzheimer’s Drug Discovery Foundation (201809-2016862)
Familjen Erling-Perssons Stiftelse
Stiftelsen för Gamla Tjänarinnor
Article History
Received: 3 June 2023
Revised: 24 June 2023
Accepted: 3 July 2023
First Online: 25 July 2023
Competing interests
: AN has received consulting fee from AVVA Pharmaceuticals, H Lundbeck A/S, Hoffman La Roche, honorarium for lecture Hoffman La Roche, Roche and hold a patent WO 2022/255915. Patent No. PCT/SE2022/050413 PET Tracers. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for Biogen, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.